Overview of the purchase price and field application of capmatinib

Introduction: Capmatinib is a targeted therapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), especially for patients with tumor mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping. This article mainly talks about the purchase method, price, mechanism of action, application fields, experimental results, contraindication groups, etc. of capmatinib.

The price of capmatinib

Currently, we know that the price of capmatinib from Lucius Pharmaceuticals in Laos is around 2,650$ to 3,000$. The price may change with market supply and demand, policy adjustments and other factors. For more details, please consult customer service staff.

How to purchase capmatinib

Capmatinib has not yet been officially launched in China, but it has been approved for use in specific medical institutions in Hainan Boao Lecheng International Medical Tourism Pilot Zone. If you have overseas relatives and friends, you can use them to help purchase capmatinib. Patients can also purchase it in areas where it is already on the market. For patients who are inconvenient to go abroad, they can choose professional overseas medical service institutions. They may cooperate with pharmacies at home and abroad and can help patients obtain medicines. Patients are advised to purchase from formal channels to avoid being deceived.

Mechanism of action of capmatinib

Capmatinib induces MET phosphorylation through various pathways such as HGF (hepatocyte growth factor) and MET amplification, thereby affecting the expression of its downstream target genes, thereby affecting the proliferation and survival of MET-dependent tumor cells. Capmatinib inhibits the growth of cancer cells driven by mutant MET variants lacking exon 14 and exhibits promising antitumor activity in a murine tumor xenograft model derived from human lung tumors.

Application indications and fields

Capmatinib is mainly used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) who have MET gene exon 14 skipping mutations (METex14). Capmatinib has been recommended by international lung cancer guidelines for the full-line treatment of METex14 exon skipping non-small cell lung cancer, and has been marketed in the United States, Japan, Brazil, and Hong Kong, my country. These guidelines and marketing approval further confirm the value and therapeutic efficacy of capmatinib in selected non-small cell lung cancer patient groups. The introduction of capmatinib provides new clinical solutions for these patients, especially in the field of precision medicine and targeted therapy.

Capmatinib trial effect

In the GEOMETRY Mono-1 trial, capmatinib showed significant efficacy in patients with non-small cell lung cancer with MET exon 14 skipping mutations. For treatment-naïve patients, capmatinib has a disease control rate of 96.4%, an objective response rate of 67.9%, a median response duration of 12.6 months, and a median progression-free survival of 9.7 months. Among previously treated patients, the overall response rate (ORR) was 41% and the median duration of response (DOR) was 9.7 months.

An updated GEOMETRY Mono-1 study data shows that capmatinib has an ORR of 68.3%, a median progression-free survival (mPFS) of 12.5 months, and a median survival (mOS) of 25.5 months in a cohort of untreated patients with MET ex14 skipping. In previously treated patients, the ORR was 44% and mPFS was 5.5 months.

Contraindicated groups for capmatinib

Pregnant women taking capmatinib may cause fetal harm. Women of childbearing potential should avoid becoming pregnant while receiving and use effective contraception during treatment and for 1 week after the last dose. Do not breastfeed during treatment with capmatinib and for one week after the last dose. The safety and effectiveness of capmatinib in pediatric patients have not been established. In patients with severe hepatic impairment, the use of capmatinib may increase the risk of adverse reactions.

Before using capmatinib, patients should consult their doctor in detail to understand their condition and treatment plan to ensure the safety and effectiveness of the medication. Patients should follow the doctor's instructions, take medications on time, and undergo regular check-ups so that the treatment plan can be adjusted in a timely manner.